Neoadjuvant Chemotherapy Therapy Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Comparisons of short-term outcomes between robot-assisted, video-assisted, and open esophagectomy for resectable esophageal cancer after neoadjuvant treatment: a retrospective study
CONCLUSIONS: Compared to VAMIE, no clear benefit exists for RAE in the treatment of resectable EC after neoadjuvant therapy. OE resulted in a longer hospital stay. Although the rate of successful right RLN node removal was higher with RAE, the clinical relevance for this is yet unclear.PMID:38617777 | PMC:PMC11009584 | DOI:10.21037/jtd-24-75 (Source: Journal of Thoracic Disease)
Source: Journal of Thoracic Disease - April 15, 2024 Category: Respiratory Medicine Authors: Ziheng Wu Jiacong Liu Lichen Zhang Muhu Tang Wenbo Shu Berend J van der Wilk Christopher J Anker Zhehao He Luming Wang Wang Lv Linhai Zhu Jian Hu Source Type: research

Biofunctional study on chemoresistance in esophageal squamous carcinoma cells induced by missense mutation of < em > NOTCH1 p.E450K < /em >
CONCLUSIONS: The NOTCH1 p.E450K point mutation causes chemotherapy resistance in KYSE140 and KYSE450 ESCC cells. Cell functional experiments showed that the NOTCH1 p.E450K point mutation enhanced the proliferation, migration and invasion abilities of KYSE140 and KYSE450 cells and increased the number of cells in S phase.PMID:38617785 | PMC:PMC11009606 | DOI:10.21037/jtd-23-1880 (Source: Journal of Thoracic Disease)
Source: Journal of Thoracic Disease - April 15, 2024 Category: Respiratory Medicine Authors: Keting Li Wentao Hao Jiwei Wu Xianben Liu Wenqun Xing Yan Zheng Source Type: research

Utility of human epidermal growth factor 2 heterogeneity as a prognostic factor in triple-negative breast cancer
AbstractIn some cases of human epidermal growth factor 2 (HER2)-negative breast cancer, including triple-negative breast cancer, HER2 expression is sporadically and strongly upregulated, a condition known asHER2 heterogeneity. We investigated the clinicopathological features of patients withHER2 heterogeneity in triple-negative breast cancers treated with neoadjuvant chemotherapy. Thirty-nine patients with triple-negative breast cancer who had undergone preoperative chemotherapy participated in this study. To assess forHER2 heterogeneity, we used dual in situ hybridization slides. We evaluated the association betweenHER2 h...
Source: Medical Molecular Morphology - April 15, 2024 Category: Molecular Biology Source Type: research

T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC
ConclusionNeoadjuvant chemoimmunotherapy drives CD8 + T cells toward a proliferative and active profile. The frequencies of CD137 + CD8 + T cells, PD-1 + Ki-67 + CD8 + T cells and Tregs at baseline might predict the response to neoadjuvant chemoimmunotherapy in NSCLC patients. The increase in IL-2 and CXCL10 might reflect the chemotaxis and enrichment of cytotoxic T cells at the tumor site and a better response to neoadjuvant chemoimmunotherapy. (Source: Cancer Immunology, Immunotherapy)
Source: Cancer Immunology, Immunotherapy - April 15, 2024 Category: Cancer & Oncology Source Type: research

Is postmastectomy radiotherapy necessary for breast cancer patients with clinically node-positive downstaging to ypN0 after neoadjuvant chemotherapy?
ConclusionIn the context of comprehensive treatments, PMRT might be exempted in ypN0 breast cancer patients. Further large-scale, randomized controlled studies are required to investigate the significance of PMRT in this patient subset. (Source: Breast Cancer Research and Treatment)
Source: Breast Cancer Research and Treatment - April 15, 2024 Category: Cancer & Oncology Source Type: research

Dysgeusia increases the risk for death and other side effects during antineoplastic systemic treatment for solid tumors: a cross-sectional study
CONCLUSIONS: Dysgeusia during CT increases the risk of other adverse effects and negatively impacts prognosis.PMID:38615256 | DOI:10.4317/medoral.26389 (Source: Medicina Oral, Patologia Oral y Cirugia Bucal)
Source: Medicina Oral, Patologia Oral y Cirugia Bucal - April 14, 2024 Category: ENT & OMF Authors: P-G Silva G-A Barreto A-C Carlos M-M Borges C-E Malta J-V Barbosa A-A Crispim S-F Jua çaba L-F Gonzaga-Silva Source Type: research